<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138097</url>
  </required_header>
  <id_info>
    <org_study_id>1218.161</org_study_id>
    <nct_id>NCT02138097</nct_id>
  </id_info>
  <brief_title>Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns</brief_title>
  <official_title>A Description of Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns Including Initiation, Switching, and Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This protocol is for a series of descriptive analyses conducted within a cohort of patients
      using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and
      non-insulin injected hypoglycemic medications between May 2011 and July 2012.

      Understanding 1) the existing utilization patterns for linagliptin, sitagliptin, saxagliptin,
      and other oral and non-insulin injected hypoglycemic agents and (2) the differences in
      utilization patterns between these agents will help with the design, analysis and
      interpretation of comparative effectiveness and safety studies of linagliptin, other DPP-4
      inhibitors, and other agents.

      The study will provide an overview of existing utilization patterns for linagliptin, other
      dipeptidyl peptidase-4 (DPP-4) inhibitors, other oral and non-insulin injected hypoglycemic
      agents, in order to detect potential selective prescribing patterns that might lead to
      channeling bias.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Initiators for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Initiators for MarketScan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Switching for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Switching for MarketScan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Augmentation for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Augmentation for MarketScan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subsequent Insulin Initiation for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subsequent Insulin Initiation for MarketScan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Discontinuation for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Discontinuation for Marketscan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days Covered for United Healthcare Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of days supply dispensed divided by number of days followed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days Covered for MarketScan Patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of days supply dispensed divided by number of days followed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 3 Months for United Healthcare Patients</measure>
    <time_frame>3 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 6 Months for United Healthcare Patients</measure>
    <time_frame>6 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 12 Months for United Healthcare Patients</measure>
    <time_frame>12 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 3 Months for MarketScan Patients</measure>
    <time_frame>3 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 6 Months for MarketScan Patients</measure>
    <time_frame>6 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence at 12 Months for MarketScan Patients</measure>
    <time_frame>12 months</time_frame>
    <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">615067</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glitazones</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Meglitinides</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-insulin injectables</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        T2DM patients aged 18 years or older, initiating antidiabetic treatment after at least 6
        months of continuous enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  diagnosis of type 2 diabetes mellitus

          -  a dispensing of an oral or non-insulin injected hypoglycemic medication between May
             2011 and June 2012

          -  at least 6 months enrolment in the database preceding the date of the first dispensing

        Exclusion criteria:

          -  age &lt; 18

          -  missing or ambiguous age or sex information

          -  at least one diagnosis of type 1 diabetes mellitus or secondary diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.161.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>September 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2015</results_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Existing data cohort design using data from the United Healthcare and MarketScan databases from May 2011 through July 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>United Healthcare</title>
          <description>Patients using an oral and non-insulin injected glucose-lowering medication identified from the United Healthcare Research database</description>
        </group>
        <group group_id="P2">
          <title>MarketScan</title>
          <description>Patients using an oral and non-insulin injected glucose-lowering medication identified from the MarketScan database.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155345"/>
                <participants group_id="P2" count="459722"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155345"/>
                <participants group_id="P2" count="459722"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients included in the study</population>
      <group_list>
        <group group_id="B1">
          <title>UHC: Glitazones</title>
          <description>Patients in the United Healthcare cohort (UHC) using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B2">
          <title>UHC: Linagliptin</title>
          <description>Patients in the United Healthcare cohort using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B3">
          <title>UHC: Meglitinides</title>
          <description>Patients in the United Healthcare cohort using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B4">
          <title>UHC: Metformin</title>
          <description>Patients in the United Healthcare cohort using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B5">
          <title>UHC: Saxagliptin</title>
          <description>Patients in the United Healthcare cohort using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B6">
          <title>UHC: Sitagliptin</title>
          <description>Patients in the United Healthcare cohort using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B7">
          <title>UHC: Sulfonylurea</title>
          <description>Patients in the United Healthcare cohort using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B8">
          <title>UHC: Alpha-Glucosidase Inhibitors</title>
          <description>Patients in the United Healthcare cohort using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B9">
          <title>UHC: GLP-I RA</title>
          <description>Patients in the United Healthcare cohort using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B10">
          <title>MS: Linagliptin</title>
          <description>Patients in the MarketScan (MS) cohort using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B11">
          <title>MS: Sitagliptin</title>
          <description>Patients in the MarketScan (MS) cohort using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B12">
          <title>MS: Saxagliptin</title>
          <description>Patients in the MarketScan (MS) cohort using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B13">
          <title>MS: Metformin</title>
          <description>Patients in the MarketScan (MS) cohort using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B14">
          <title>MS: Sulfonylurea</title>
          <description>Patients in the MarketScan (MS) cohort using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B15">
          <title>MS: Glitazones</title>
          <description>Patients in the MarketScan (MS) cohort using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B16">
          <title>MS: Meglitinides</title>
          <description>Patients in the MarketScan (MS) cohort using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B17">
          <title>MS: Alpha-Glucosidase Inhibitors</title>
          <description>Patients in the MarketScan (MS) cohort using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B18">
          <title>MS: GLP-I RA</title>
          <description>Patients in the MarketScan (MS) cohort using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7203"/>
            <count group_id="B2" value="2820"/>
            <count group_id="B3" value="1184"/>
            <count group_id="B4" value="72694"/>
            <count group_id="B5" value="8100"/>
            <count group_id="B6" value="18491"/>
            <count group_id="B7" value="33868"/>
            <count group_id="B8" value="495"/>
            <count group_id="B9" value="10490"/>
            <count group_id="B10" value="7708"/>
            <count group_id="B11" value="58769"/>
            <count group_id="B12" value="24550"/>
            <count group_id="B13" value="205213"/>
            <count group_id="B14" value="104422"/>
            <count group_id="B15" value="22310"/>
            <count group_id="B16" value="5412"/>
            <count group_id="B17" value="1918"/>
            <count group_id="B18" value="29420"/>
            <count group_id="B19" value="615067"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.67" spread="9.99"/>
                    <measurement group_id="B2" value="55.90" spread="10.06"/>
                    <measurement group_id="B3" value="57.08" spread="10.46"/>
                    <measurement group_id="B4" value="52.57" spread="10.56"/>
                    <measurement group_id="B5" value="53.68" spread="9.66"/>
                    <measurement group_id="B6" value="54.40" spread="10.16"/>
                    <measurement group_id="B7" value="53.75" spread="10.40"/>
                    <measurement group_id="B8" value="55.93" spread="10.67"/>
                    <measurement group_id="B9" value="52.35" spread="9.54"/>
                    <measurement group_id="B10" value="58.72" spread="11.66"/>
                    <measurement group_id="B11" value="58.42" spread="11.98"/>
                    <measurement group_id="B12" value="56.84" spread="11.39"/>
                    <measurement group_id="B13" value="55.91" spread="12.08"/>
                    <measurement group_id="B14" value="57.94" spread="12.49"/>
                    <measurement group_id="B15" value="57.40" spread="11.66"/>
                    <measurement group_id="B16" value="62.50" spread="12.60"/>
                    <measurement group_id="B17" value="59.96" spread="12.00"/>
                    <measurement group_id="B18" value="54.28" spread="10.02"/>
                    <measurement group_id="B19" value="55.05" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2679"/>
                    <measurement group_id="B2" value="1175"/>
                    <measurement group_id="B3" value="505"/>
                    <measurement group_id="B4" value="32251"/>
                    <measurement group_id="B5" value="3400"/>
                    <measurement group_id="B6" value="7600"/>
                    <measurement group_id="B7" value="13631"/>
                    <measurement group_id="B8" value="201"/>
                    <measurement group_id="B9" value="5521"/>
                    <measurement group_id="B10" value="3368"/>
                    <measurement group_id="B11" value="26158"/>
                    <measurement group_id="B12" value="10838"/>
                    <measurement group_id="B13" value="97105"/>
                    <measurement group_id="B14" value="45668"/>
                    <measurement group_id="B15" value="9181"/>
                    <measurement group_id="B16" value="2526"/>
                    <measurement group_id="B17" value="909"/>
                    <measurement group_id="B18" value="16077"/>
                    <measurement group_id="B19" value="278793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4524"/>
                    <measurement group_id="B2" value="1645"/>
                    <measurement group_id="B3" value="679"/>
                    <measurement group_id="B4" value="40443"/>
                    <measurement group_id="B5" value="4700"/>
                    <measurement group_id="B6" value="10891"/>
                    <measurement group_id="B7" value="20237"/>
                    <measurement group_id="B8" value="294"/>
                    <measurement group_id="B9" value="4969"/>
                    <measurement group_id="B10" value="4340"/>
                    <measurement group_id="B11" value="32611"/>
                    <measurement group_id="B12" value="13712"/>
                    <measurement group_id="B13" value="108108"/>
                    <measurement group_id="B14" value="58754"/>
                    <measurement group_id="B15" value="13129"/>
                    <measurement group_id="B16" value="2886"/>
                    <measurement group_id="B17" value="1009"/>
                    <measurement group_id="B18" value="13343"/>
                    <measurement group_id="B19" value="336274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Initiators for United Healthcare Patients</title>
        <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in the United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Initiators for United Healthcare Patients</title>
          <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
          <population>All subjects in the United Healthcare cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="495"/>
                <count group_id="O9" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naive new users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="69.9"/>
                    <measurement group_id="O5" value="2.3"/>
                    <measurement group_id="O6" value="5.8"/>
                    <measurement group_id="O7" value="16.3"/>
                    <measurement group_id="O8" value="0.1"/>
                    <measurement group_id="O9" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-naive new users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="23.0"/>
                    <measurement group_id="O5" value="8.2"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="27.5"/>
                    <measurement group_id="O8" value="0.5"/>
                    <measurement group_id="O9" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="67.4"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="6.0"/>
                    <measurement group_id="O7" value="15.9"/>
                    <measurement group_id="O8" value="0.2"/>
                    <measurement group_id="O9" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dual Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="6.3"/>
                    <measurement group_id="O6" value="13.6"/>
                    <measurement group_id="O7" value="28.5"/>
                    <measurement group_id="O8" value="0.1"/>
                    <measurement group_id="O9" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other initiation other than mono- or dual therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="13.0"/>
                    <measurement group_id="O5" value="9.1"/>
                    <measurement group_id="O6" value="21.3"/>
                    <measurement group_id="O7" value="24.5"/>
                    <measurement group_id="O8" value="0.9"/>
                    <measurement group_id="O9" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Initiators for MarketScan Patients</title>
        <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Initiators for MarketScan Patients</title>
          <description>Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.</description>
          <population>All subjects in MarketScan cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="1918"/>
                <count group_id="O9" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naive new users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="69.1"/>
                    <measurement group_id="O5" value="2.1"/>
                    <measurement group_id="O6" value="5.9"/>
                    <measurement group_id="O7" value="17.2"/>
                    <measurement group_id="O8" value="0.1"/>
                    <measurement group_id="O9" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-naive new users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="23.2"/>
                    <measurement group_id="O5" value="8.1"/>
                    <measurement group_id="O6" value="18.8"/>
                    <measurement group_id="O7" value="27.5"/>
                    <measurement group_id="O8" value="0.7"/>
                    <measurement group_id="O9" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="66.1"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="6.3"/>
                    <measurement group_id="O7" value="17.4"/>
                    <measurement group_id="O8" value="0.2"/>
                    <measurement group_id="O9" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dual Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="34.0"/>
                    <measurement group_id="O5" value="6.6"/>
                    <measurement group_id="O6" value="15.6"/>
                    <measurement group_id="O7" value="29.7"/>
                    <measurement group_id="O8" value="0.3"/>
                    <measurement group_id="O9" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other initiation other than mono- or dual therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="16.9"/>
                    <measurement group_id="O5" value="9.0"/>
                    <measurement group_id="O6" value="21.8"/>
                    <measurement group_id="O7" value="21.4"/>
                    <measurement group_id="O8" value="1.1"/>
                    <measurement group_id="O9" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Switching for United Healthcare Patients</title>
        <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Switching for United Healthcare Patients</title>
          <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
          <population>All subjects in United Healthcare cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.76"/>
                    <measurement group_id="O2" value="71.64"/>
                    <measurement group_id="O3" value="122.97"/>
                    <measurement group_id="O4" value="30.47"/>
                    <measurement group_id="O5" value="57.38"/>
                    <measurement group_id="O6" value="103.09"/>
                    <measurement group_id="O7" value="46.89"/>
                    <measurement group_id="O8" value="87.6"/>
                    <measurement group_id="O9" value="126.83"/>
                    <measurement group_id="O10" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Switching for MarketScan Patients</title>
        <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Switching for MarketScan Patients</title>
          <description>Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days</description>
          <population>All subjects in MarketScan cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.35"/>
                    <measurement group_id="O2" value="72.48"/>
                    <measurement group_id="O3" value="96.88"/>
                    <measurement group_id="O4" value="27.81"/>
                    <measurement group_id="O5" value="60.31"/>
                    <measurement group_id="O6" value="52.25"/>
                    <measurement group_id="O7" value="40.87"/>
                    <measurement group_id="O8" value="54.33"/>
                    <measurement group_id="O9" value="102.9"/>
                    <measurement group_id="O10" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Augmentation for United Healthcare Patients</title>
        <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Augmentation for United Healthcare Patients</title>
          <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
          <population>All patients in United Healthcare cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.04"/>
                    <measurement group_id="O2" value="274.68"/>
                    <measurement group_id="O3" value="331.17"/>
                    <measurement group_id="O4" value="204.43"/>
                    <measurement group_id="O5" value="269.02"/>
                    <measurement group_id="O6" value="340.69"/>
                    <measurement group_id="O7" value="252.08"/>
                    <measurement group_id="O8" value="317.89"/>
                    <measurement group_id="O9" value="330.95"/>
                    <measurement group_id="O10" value="199.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Augmentation for MarketScan Patients</title>
        <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Augmentation for MarketScan Patients</title>
          <description>Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy</description>
          <population>All patients in MarketScan cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.93"/>
                    <measurement group_id="O2" value="309.36"/>
                    <measurement group_id="O3" value="269.53"/>
                    <measurement group_id="O4" value="201.04"/>
                    <measurement group_id="O5" value="275.57"/>
                    <measurement group_id="O6" value="237.31"/>
                    <measurement group_id="O7" value="226.11"/>
                    <measurement group_id="O8" value="248.28"/>
                    <measurement group_id="O9" value="287.85"/>
                    <measurement group_id="O10" value="184.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subsequent Insulin Initiation for United Healthcare Patients</title>
        <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Subsequent Insulin Initiation for United Healthcare Patients</title>
          <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
          <population>All patients in United Healthcare cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.61"/>
                    <measurement group_id="O2" value="101.17"/>
                    <measurement group_id="O3" value="162.97"/>
                    <measurement group_id="O4" value="56.49"/>
                    <measurement group_id="O5" value="97.37"/>
                    <measurement group_id="O6" value="103.26"/>
                    <measurement group_id="O7" value="92.02"/>
                    <measurement group_id="O8" value="101.44"/>
                    <measurement group_id="O9" value="142.42"/>
                    <measurement group_id="O10" value="135.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subsequent Insulin Initiation for MarketScan Patients</title>
        <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Subsequent Insulin Initiation for MarketScan Patients</title>
          <description>Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months</description>
          <population>All patients in MarketScan cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1"/>
                    <measurement group_id="O2" value="111.02"/>
                    <measurement group_id="O3" value="168.83"/>
                    <measurement group_id="O4" value="57.99"/>
                    <measurement group_id="O5" value="105.7"/>
                    <measurement group_id="O6" value="103.65"/>
                    <measurement group_id="O7" value="89.57"/>
                    <measurement group_id="O8" value="103.85"/>
                    <measurement group_id="O9" value="191.54"/>
                    <measurement group_id="O10" value="136.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Discontinuation for United Healthcare Patients</title>
        <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Discontinuation for United Healthcare Patients</title>
          <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
          <population>All subjects in United Healthcare cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.32"/>
                    <measurement group_id="O2" value="287.61"/>
                    <measurement group_id="O3" value="466.55"/>
                    <measurement group_id="O4" value="293.23"/>
                    <measurement group_id="O5" value="267.60"/>
                    <measurement group_id="O6" value="267.75"/>
                    <measurement group_id="O7" value="288.55"/>
                    <measurement group_id="O8" value="266.83"/>
                    <measurement group_id="O9" value="479.31"/>
                    <measurement group_id="O10" value="337.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Discontinuation for Marketscan Patients</title>
        <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
        <time_frame>up to 12 months</time_frame>
        <population>All subjects in Marketscan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Discontinuation for Marketscan Patients</title>
          <description>Number of patients with a treatment gap of &gt;=6 months (i.e., no dispensing of non-insulin hypoglycemic agents within 6 months after the end of days supplied)</description>
          <population>All subjects in Marketscan cohort</population>
          <units>participants/1000 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522.1"/>
                    <measurement group_id="O2" value="284.67"/>
                    <measurement group_id="O3" value="463.13"/>
                    <measurement group_id="O4" value="285.58"/>
                    <measurement group_id="O5" value="261.2"/>
                    <measurement group_id="O6" value="262.24"/>
                    <measurement group_id="O7" value="285.75"/>
                    <measurement group_id="O8" value="261.06"/>
                    <measurement group_id="O9" value="504.83"/>
                    <measurement group_id="O10" value="333.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days Covered for United Healthcare Patients</title>
        <description>Number of days supply dispensed divided by number of days followed</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days Covered for United Healthcare Patients</title>
          <description>Number of days supply dispensed divided by number of days followed</description>
          <population>All patients in United Healthcare cohort</population>
          <units>days covered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.79" spread="19.68"/>
                    <measurement group_id="O2" value="77.54" spread="18.91"/>
                    <measurement group_id="O3" value="64.04" spread="19.94"/>
                    <measurement group_id="O4" value="70.37" spread="20.31"/>
                    <measurement group_id="O5" value="75.81" spread="19.30"/>
                    <measurement group_id="O6" value="73.09" spread="19.30"/>
                    <measurement group_id="O7" value="72.46" spread="20.58"/>
                    <measurement group_id="O8" value="74.03" spread="19.32"/>
                    <measurement group_id="O9" value="67.48" spread="19.62"/>
                    <measurement group_id="O10" value="68.34" spread="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days Covered for MarketScan Patients</title>
        <description>Number of days supply dispensed divided by number of days followed</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days Covered for MarketScan Patients</title>
          <description>Number of days supply dispensed divided by number of days followed</description>
          <population>All patients in MarketScan cohort</population>
          <units>days covered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.04" spread="19.82"/>
                    <measurement group_id="O2" value="78.62" spread="19.15"/>
                    <measurement group_id="O3" value="69.58" spread="20.56"/>
                    <measurement group_id="O4" value="74.40" spread="20.20"/>
                    <measurement group_id="O5" value="78.13" spread="19.34"/>
                    <measurement group_id="O6" value="77.80" spread="19.78"/>
                    <measurement group_id="O7" value="76.09" spread="20.28"/>
                    <measurement group_id="O8" value="78.00" spread="19.61"/>
                    <measurement group_id="O9" value="69.82" spread="20.38"/>
                    <measurement group_id="O10" value="71.30" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 3 Months for United Healthcare Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
        <time_frame>3 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 3 Months for United Healthcare Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in United Healthcare cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.90"/>
                    <measurement group_id="O2" value="82.84"/>
                    <measurement group_id="O3" value="59.12"/>
                    <measurement group_id="O4" value="70.63"/>
                    <measurement group_id="O5" value="81.40"/>
                    <measurement group_id="O6" value="77.27"/>
                    <measurement group_id="O7" value="73.2"/>
                    <measurement group_id="O8" value="78.79"/>
                    <measurement group_id="O9" value="65.86"/>
                    <measurement group_id="O10" value="68.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 6 Months for United Healthcare Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
        <time_frame>6 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 6 Months for United Healthcare Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in United Healthcare cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.02"/>
                    <measurement group_id="O2" value="64.65"/>
                    <measurement group_id="O3" value="34.29"/>
                    <measurement group_id="O4" value="48.38"/>
                    <measurement group_id="O5" value="62.90"/>
                    <measurement group_id="O6" value="55.41"/>
                    <measurement group_id="O7" value="51.71"/>
                    <measurement group_id="O8" value="57.95"/>
                    <measurement group_id="O9" value="39.80"/>
                    <measurement group_id="O10" value="47.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 12 Months for United Healthcare Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
        <time_frame>12 months</time_frame>
        <population>All patients in United Healthcare cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 12 Months for United Healthcare Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in United Healthcare cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7203"/>
                <count group_id="O2" value="2820"/>
                <count group_id="O3" value="1184"/>
                <count group_id="O4" value="72694"/>
                <count group_id="O5" value="8100"/>
                <count group_id="O6" value="18491"/>
                <count group_id="O7" value="33868"/>
                <count group_id="O8" value="25940"/>
                <count group_id="O9" value="495"/>
                <count group_id="O10" value="10490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.35"/>
                    <measurement group_id="O2" value="51.45"/>
                    <measurement group_id="O3" value="22.64"/>
                    <measurement group_id="O4" value="35.45"/>
                    <measurement group_id="O5" value="49.75"/>
                    <measurement group_id="O6" value="36.84"/>
                    <measurement group_id="O7" value="38.58"/>
                    <measurement group_id="O8" value="40.95"/>
                    <measurement group_id="O9" value="25.05"/>
                    <measurement group_id="O10" value="33.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 3 Months for MarketScan Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
        <time_frame>3 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 3 Months for MarketScan Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 3 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in MarketScan cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.47"/>
                    <measurement group_id="O2" value="83.39"/>
                    <measurement group_id="O3" value="68.90"/>
                    <measurement group_id="O4" value="76.89"/>
                    <measurement group_id="O5" value="82.82"/>
                    <measurement group_id="O6" value="81.58"/>
                    <measurement group_id="O7" value="78.72"/>
                    <measurement group_id="O8" value="82.12"/>
                    <measurement group_id="O9" value="69.08"/>
                    <measurement group_id="O10" value="73.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 6 Months for MarketScan Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
        <time_frame>6 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 6 Months for MarketScan Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 6 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in MarketScan cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.70"/>
                    <measurement group_id="O2" value="62.91"/>
                    <measurement group_id="O3" value="39.32"/>
                    <measurement group_id="O4" value="51.37"/>
                    <measurement group_id="O5" value="63.07"/>
                    <measurement group_id="O6" value="59.54"/>
                    <measurement group_id="O7" value="53.87"/>
                    <measurement group_id="O8" value="60.80"/>
                    <measurement group_id="O9" value="39.62"/>
                    <measurement group_id="O10" value="48.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence at 12 Months for MarketScan Patients</title>
        <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
        <time_frame>12 months</time_frame>
        <population>All patients in MarketScan cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glitazones</title>
            <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O3">
            <title>Meglitinides</title>
            <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O5">
            <title>Saxagliptin</title>
            <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin</title>
            <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O7">
            <title>Sulfonylurea</title>
            <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O8">
            <title>Other DPP-4I</title>
            <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O9">
            <title>Alpha-Glucosidase Inhibitors</title>
            <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
          <group group_id="O10">
            <title>GLP-I RA</title>
            <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence at 12 Months for MarketScan Patients</title>
          <description>Fraction of non-insulin hypoglycemic initiators with continued dispensing. Patients will be classified as persistent if they possess medication at 12 months. Grace period of 30 days will be allowed.</description>
          <population>All patients in MarketScan cohort</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22310"/>
                <count group_id="O2" value="7708"/>
                <count group_id="O3" value="5412"/>
                <count group_id="O4" value="205213"/>
                <count group_id="O5" value="24550"/>
                <count group_id="O6" value="58769"/>
                <count group_id="O7" value="104422"/>
                <count group_id="O8" value="81760"/>
                <count group_id="O9" value="1918"/>
                <count group_id="O10" value="29420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.04"/>
                    <measurement group_id="O2" value="50.30"/>
                    <measurement group_id="O3" value="27.18"/>
                    <measurement group_id="O4" value="39.32"/>
                    <measurement group_id="O5" value="50.15"/>
                    <measurement group_id="O6" value="46.83"/>
                    <measurement group_id="O7" value="41.60"/>
                    <measurement group_id="O8" value="47.95"/>
                    <measurement group_id="O9" value="27.27"/>
                    <measurement group_id="O10" value="35.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and other (non-serious) adverse events were not of interest in this study and therefore were not collected or assessed as part of the study, in addition individual patient data is not available therefore adverse event data is not presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glitazones</title>
          <description>Patients using Glitazones as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin</title>
          <description>Patients using Linagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E3">
          <title>Meglitinides</title>
          <description>Patients using Meglitinides as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E4">
          <title>Metformin</title>
          <description>Patients using Metformin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E5">
          <title>Saxagliptin</title>
          <description>Patients using Saxagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E6">
          <title>Sitagliptin</title>
          <description>Patients using Sitagliptin as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E7">
          <title>Sulfonylurea</title>
          <description>Patients using Sulfonylurea as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E8">
          <title>Other DPP-4I</title>
          <description>Patients using other dipeptidyl peptidase-4 inhibitors (DPP-4I) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E9">
          <title>Alpha-Glucosidase Inhibitors</title>
          <description>Patients using Alpha-Glucosidase Inhibitors (AGI) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
        <group group_id="E10">
          <title>GLP-I RA</title>
          <description>Patients using glucagon-like peptide-1 (GLP-1) receptor agonists (RA) as an oral and non-insulin injected glucose-lowering medication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIs intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

